Intercellular adhesion molecules, and their binding ligands
AssigneeDana-Farber Cancer Institute, Inc.
InventorsTimothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunsuppressive agents.
Claims11
A pharmaceutical composition comprising a pharmaceutically acceptable excipient, at least one immunosuppressive agent, and an anti-ICAM-1 antibody, or a fragment of said anti-ICAM-1 antibody, which is capable of binding to ICAM-1 and blocking the interaction of ICAM-1 with leukocytes in vivo.
A method of decreasing the severity of inflammation associated with the leukocyte/ICAM-1 interaction comprising administration of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an anti-ICAm-1 antibody, or a fragment of said anti-ICAM-1 antibody, which is capable of binding to ICAM-1 and blocking the interaction of ICAM-1 with leukocytes.
Dependencies are inferred from the claim text.